09:42 AM EST - Cardiol Therapeutics Inc. : Announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase III randomized, double-blind, placebo-controlled, multi-center international trial evaluating CardiolRx™ for the prevention of disease recurrence in patients with recurrent pericarditis. Cardiol Therapeutics Inc.
shares T.CRDL are trading unchanged at $1.35.
